The New England journal of medicine, 2018-11, Vol.379 (21), p.2040-2051
- Paz-Ares, Luis
- Luft, Alexander
- Vicente, David
- Tafreshi, Ali
- Gümüş, Mahmut
- Mazières, Julien
- Hermes, Barbara
- Çay Şenler, Filiz
- Csőszi, Tibor
- Fülöp, Andrea
- Rodríguez-Cid, Jerónimo
- Wilson, Jonathan
- Sugawara, Shunichi
- Kato, Terufumi
- Lee, Ki Hyeong
- Cheng, Ying
- Novello, Silvia
- Halmos, Balazs
- Li, Xiaodong
- Lubiniecki, Gregory M
- Piperdi, Bilal
- Kowalski, Dariusz M
2018
Volltextzugriff (PDF)
Details
- Autor(en) / Beteiligte
- Paz-Ares, Luis
- Luft, Alexander
- Vicente, David
- Tafreshi, Ali
- Gümüş, Mahmut
- Mazières, Julien
- Hermes, Barbara
- Çay Şenler, Filiz
- Csőszi, Tibor
- Fülöp, Andrea
- Rodríguez-Cid, Jerónimo
- Wilson, Jonathan
- Sugawara, Shunichi
- Kato, Terufumi
- Lee, Ki Hyeong
- Cheng, Ying
- Novello, Silvia
- Halmos, Balazs
- Li, Xiaodong
- Lubiniecki, Gregory M
- Piperdi, Bilal
- Kowalski, Dariusz M
- Titel
- Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
- Ist Teil von
- The New England journal of medicine, 2018-11, Vol.379 (21), p.2040-2051
- Ort / Verlag
- United States: Massachusetts Medical Society
- Erscheinungsjahr
- 2018
- Quelle
- MEDLINE
- Beschreibungen/Notizen
- The addition of pembrolizumab, an anti–PD-1 antibody, to a platinum–taxane chemotherapy combination significantly prolonged progression-free and overall survival among patients with untreated squamous cell lung cancer, regardless of the level of tumor PD-L1 expression.
- Sprache
- Englisch
- Identifikatoren
- ISSN: 0028-4793eISSN: 1533-4406DOI: 10.1056/NEJMoa1810865Titel-ID: cdi_hal_primary_oai_HAL_hal_02345238v1
- Format
- –
- Schlagworte
- Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Humanized - administration & dosage, Antibodies, Monoclonal, Humanized - adverse effects, Antineoplastic Combined Chemotherapy Protocols - adverse effects, Antineoplastic Combined Chemotherapy Protocols - therapeutic use, Apoptosis, Cancer therapies, Carboplatin, Carboplatin - administration & dosage, Carcinoma, Non-Small-Cell Lung - drug therapy, Carcinoma, Non-Small-Cell Lung - mortality, Carcinoma, Non-Small-Cell Lung - secondary, Chemotherapy, Clinical trials, Death, Double-Blind Method, Evidence-based medicine, Female, Histamine, Humans, Immunotherapy, Intention to Treat Analysis, Life Sciences, Lung cancer, Lung Neoplasms - drug therapy, Lung Neoplasms - mortality, Male, Metastases, Metastasis, Middle Aged, Monoclonal antibodies, Nanoparticles, Non-small cell lung carcinoma, Paclitaxel, Paclitaxel - administration & dosage, Patients, PD-L1 protein, Pembrolizumab, Platinum, Programmed Cell Death 1 Receptor - antagonists & inhibitors, Progression-Free Survival, Statistical analysis, Survival Analysis, Targeted cancer therapy, Tumor cells